Evidence map›Paper›PMID 41234719›Full record

ReviewFrontiers in oncology2025

Progress of long-chain noncoding small nucleolar RNA host genes in thyroid cancer.

Tingyu Yang, Yuanxu Xie

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tingyu YangBishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China.
Yuanxu XieBishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small nucleolar RNA host genes (SNHGs) are a class of long non-coding RNAs that are widely aberrantly expressed in thyroid cancer and regulate tumor progression through the "SNHG-miRNA-signaling pathway" network. SNHG7 promotes cell proliferation and metastasis via the PI3K/Akt pathway and correlates with radioactive iodine resistance; SNHG15 accelerates epithelial-mesenchymal transition via the Hippo-YAP1 pathway; SNHG12 drives malignant phenotypes by interacting with Wnt/β-catenin signaling; SNHG14 enhances tumor invasion through multiple miRNA axes. In contrast, SNHG3 and SNHG5 exhibit tumor-suppressive effects in some studies. Overall, SNHGs may serve as molecular biomarkers and hold potential therapeutic target value. However, existing evidence is largely based on

Indexed as

competitive endogenous RNAepithelial-mesenchymal transitionlong noncoding RNAnucleolar RNA host genesthyroid carcinoma

Identifiers

PMID41234719
PMCPMC12605098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.